<DOC>
	<DOCNO>NCT01424436</DOCNO>
	<brief_summary>Modulation beta-amyloid level CSF plasma GSK933776 patient mild Alzheimer 's disease mild cognitive impairment</brief_summary>
	<brief_title>Modulation Abeta Levels GSK933776 Alzheimer 's Disease Patient</brief_title>
	<detailed_description>This phase I , open label , single dose parallel group study assess short term pharmacodynamics safety GSK933776 . The effect beta amyloid level assess early ( MCI ) mild Alzheimer 's disease ( AD ) patient single dose GSK933776 i.v . administration .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Probable mild Alzheimer 's disease ( MMSE 2026 ) mild cognitive impairment Increase total tau ptau CSF Decrease amyloid beta CSF Stable dose cholinesterase inhibitor , memantine selegine treatment Body weight less 120 kg Willingness comply contraceptive method self partner childbearing potential Any cause dementia Other significant neurologic psychiatric illness Hachinski Ischemia Score &gt; 4 More 3 microbleeds MRI Type 2 diabetes control diet Risk cerebrovascular disease , cerebral haemorrhage stroke History systemic autoimmune disease Use platelet antiaggregates anticoagulant ( Aspirin 325 mg/day allowable ) Use chronic corticosteroid Uncontrolled hypertension spite antihypertensive medication Renal hepatic insufficiency clinically significant anaemia In nursing home care Contraindications lumbar puncture MRI Prior participation therapeutic study adequate washout period</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CSF sample</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Amyloid beta level</keyword>
</DOC>